J. Narayan

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India

K. Dhingra, B. Borkakoty, S. Gupta, 2021, medRxiv.

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Kelly A. Fusco, Maria Cristina Lopes, D. Devine, 2021, Nature Medicine.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.